Post USFDA warning letter, Amazon removing 7 unapproved eye drops from its e-commerce platform

The eye drops flagged in the letter to Amazon include Similasan Pink Eye Relief, Can-C Eye Drops, Optique 1 Eye Drops and OcluMed Eye Drops, among others.

Published On 2023-11-16 10:00 GMT   |   Update On 2023-11-16 11:39 GMT

Amazon said on Wednesday it was in the process of removing seven unapproved eye drops from its e-commerce platform following a warning letter from the U.S. health regulator earlier this week.The products in question have been investigated and are in the process of being removed, a company spokesperson said.The U.S. Food and Drug Administration (FDA) on Monday sent a warning letter to Amazon...

Login or Register to read the full article

Amazon said on Wednesday it was in the process of removing seven unapproved eye drops from its e-commerce platform following a warning letter from the U.S. health regulator earlier this week.

The products in question have been investigated and are in the process of being removed, a company spokesperson said.

The U.S. Food and Drug Administration (FDA) on Monday sent a warning letter to Amazon for selling eye drops which have not been recognized as safe and effective in providing temporary relief from symptoms such as excessive watery discharge, redness, burning and pink eye.

The eye drops flagged in the letter to Amazon include Similasan Pink Eye Relief, Can-C Eye Drops, Optique 1 Eye Drops and OcluMed Eye Drops, among others.

The FDA has warned consumers against using 26 over-the-counter eye drops due to risk of infection and some cases of possible vision loss.

Read also: USFDA warns against use of 26 over-the-counter eye drop products

The health agency also sent warning letters to eight other companies in September, including pharmacy giants CVS Health and Walgreens Boots Alliance, against manufacturing or marketing of certain unapproved eye products.


Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News